Company profilePharmaceutical#78 of 1,318 in Pakistan✓ No DRAP alerts

The Searle Company Limited

Pharmaceutical company · 193 brands · 134 molecules

Ranked #9 of 62 companies in Antivirals For Systemic Use

193 registered products 58 pharmaceutical brands 134 distinct molecules 0 DRAP alerts

Company overview

193
registered products
58
pharmaceutical brands
134
distinct molecules
12
therapeutic classes
0
DRAP alerts

The Searle Company Limited is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 193 product registrations across 134 distinct molecules. It is the 78th largest registrant in Pakistan by product count, and ranks 9th of 62 in Antivirals For Systemic Use. Its portfolio is concentrated in Antivirals For Systemic Use and Anti-Infectives. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Reported financials

PSX-listed · fiscal year 2024 (June 30, 2024)

29.4B PKR
revenue

Revenue up 12% YoY (26.18B → 29.4B). Swung to net loss on impairment from SPL divestment decision. Gross margin 51% TTM.

Source: company filing

Products by The

27 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

26
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
202626

Top molecules by brand count

Amlodipine6 brands
Haloperidol6 brands
Verapamil5 brands
Bevacizumab4 brands
Sterile Water For Injection4 brands
Cefixime4 brands
Ribavirin4 brands

Therapeutic classes

Antivirals For Systemic Use · 5Anti-Infectives · 3Cardiac Care · 2Neuro · 2Quinolone Antibacterials · 2Antineoplastics · 2Diuretic · 1Antiepileptics · 1Macrolides, Lincosamides And Streptogramins · 1Antidiarrheals, Intestinal Antiinflammatory/Antiinfective · 1Other Analgesics And Antipyretics · 1Respiratory Care · 1

Conditions treated

General Infections · 3Hypertension · 2Epilepsy/Convulsion · 2Asthma/Copd · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official209 products · Rs 4.81 – Rs 132,267.99
DVAGO13 products · Rs 29.8 – Rs 810.4
Servaid14 products · Rs 112 – Rs 1,650
Median across source: Rs 387.5

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

SEARLE PAKISTAN (PVT.) LTD. holds 228 molecules not in this portfolio
AcetazolamideAdalimumabAlprazolamAmilorideAminophyllineAmitriptyline
GETZ PHARMA PAKISTAN (PVT) LTD. holds 265 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAlbendazole
MACTER INTERNATIONAL (PVT) LTD. holds 172 molecules not in this portfolio
000 I.U10Ug Polysaccharides Covalently Bound To 20Ug To 32Ug Of Tetanus ToxoidAlbendazoleAlbuterolAlfacalcidolAluminium Hydroxide

Get the full profile for The

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.